Genscript Biotech Corporation (G51) — Cash Flow Quality Index
Genscript Biotech Corporation (G51) has a Cash Flow Quality Index of 0.03x as of December 2024. Operating cash flow of €75.65 Million is below net income of €2.96 Billion, suggesting accrual-heavy earnings not yet converted to cash. Also explore Genscript Biotech Corporation assets under control for the complete picture of this company's asset base.
Cash Flow Quality Index
Operating Cash Flow
Net Income
Data as of
Genscript Biotech Corporation Cash Flow Quality Index (2016–2024)
Historical Cash Flow Quality Index for Genscript Biotech Corporation across 4 annual periods. Values consistently above 1.0x indicate high-quality earnings. Check Genscript Biotech Corporation (G51) tangible equity ratio to evaluate the tangible quality of the company's equity base.
Annual Cash Flow Quality Index for Genscript Biotech Corporation (2016–2024)
Year-by-year earnings quality comparison for Genscript Biotech Corporation. For live market cap and the full company financial profile, see G51 stock market capitalisation.
| Year | Quality Index | Operating CF (EUR) | Net Income | YoY Change |
|---|---|---|---|---|
| 2024 | 0.03x | €75.65 Million | €2.96 Billion | ▼ -99.8% |
| 2018 | 14.50x | €307.66 Million | €21.22 Million | ▲ +1672.8% |
| 2017 | 0.82x | €21.37 Million | €26.12 Million | ▼ -35.7% |
| 2016 | 1.27x | €33.27 Million | €26.17 Million | — |